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Abstract Introduction: The effects of any drug treatment
on cognitive function are typically studied in groups of
subjects. Observations made about the behavior of the drug,
in the study sample, are then generalized to the population
from which the sample was drawn. However, the
magnitude and pharmacodynamic qualities of the response
to many central nervous system-active drugs are known to
vary in the population. Therefore, it is useful to consider
statistical models for the detection of cognitive change in
response to a drug treatment in individual subjects.
Materials and methods: In this report, we first outline
the statistical assumptions and requirements for the reliable
estimation of clinically relevant individual change in
cognition. We then used the sedative benzodiazepine,
alprazolam, as a pharmacologic challenge in healthy
volunteer subjects to test our statistical model, using a
parallel groups placebo-controlled study design. After
treatment, the nature and severity of alprazolam-induced
cognitive change was determined for each individual.
Results: Our proposed method and analysis showed an
excellent sensitivity and specificity for alprazolam-related
cognitive deterioration in individuals. Discussion and
conclusions: These findings, although preliminary, sug-
gest that statistically reliable decisions about the effects of
sedative drugs on cognition can be made for individuals.
Introduction
Most conclusions about the psychoactive effects of licensed
or novel drugs are based on the comparison of cognitive
measures between or within groups of subjects. For example,
the effects of a drug on cognitive function are determined
optimally by comparing the average cognitive performance
of a group of subjects, after drug treatment to that of the same
group, or a matched group, who have been treated with a
placebo (e.g., Hinkle et al. 1996). Observations made about
the behavior of the drug in the study sample are generalized
to the population from which the sample was drawn (e.g.,
healthy adults, patients with psychiatric disorder). However,
there is a growing awareness that response to psychoactive
drugs may vary in the population and that some of this
variation can be explained by subject-specific factors such as
physical characteristics, disease severity, or genetic status
(e.g., Macher and Corcq 2004; Calabrese et al. 2004; Lesch
and Gutknecht 2004). Therefore, it is appropriate to develop
statistical models for the detection of cognitive change in
response to a drug treatment in individual subjects. For
example, it is well known that not all study subjects show the
expected cognitive response to drug challenges (e.g., treat-
ment nonresponders Redelmeier and Tversky 1990). The
identification and study of “treatment nonresponders” or
“treatment responders” could provide critical information for
understanding population variability, for design of future
studies, for fine-tuning of subject inclusion criteria, and
eventually for regulatory labelling. Second, the ability to
measure cognitive effects reliably in individuals may
increase the statistical power of small phase I and II studies.
With this approach, individuals who do not respond to a
treatment based on prospectively defined criteria might be
removed or replaced with “treatment responders”. Third, the
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assist clinicians in determiningwhether their patients respond
to a treatment as expected from published clinical trial data.
The definition of a cognitive response or nonresponse to
treatment requires that some criterion for either be defined on
a specific outcome measure (Guyatt et al. 1997; Macher and
Corcq 2004). The definition of such a criterion for change in
cognitive performance in individuals requires that at least
three issues be considered. First, any criterion value for
classifying change will contain error and this error is greater
for individuals than groups (Jenkinson 1995; Williams and
Naylor 1992). Therefore, the magnitude of change in a
cognitive outcome measure necessary to be classified as
statistically significant or clinically meaningful in an
individual may need to be greater than that required for a
group of subjects. Second, if a criterion value for classifying
cognitive change in individuals is estimated from a group
study, then this criterion will also contain error. Without
appreciating the magnitude of this error, individuals whose
performance has merely exceeded the group-derived crite-
rion may be considered to have truly changed, even though
the change value is within the range of error associated with
the criterion (Redelmeier and Tversky 1990). Third, while
these two issues are relevant when cognitive change is
defined using a single cognitive performance measure, most
studies of the cognitive change in response to drug treatment
actually use multiple performance measures. This is because
qualitative differences in the patterns of treatment-related
change across measures can be used to characterize the
effects of different drugs or different doses of the same drug.
However, as the number of performance measures used to
define cognitive impairment in individuals increases, the
probability of false positive classification also increases. For
group studies, this risk is well understood and corrections in
Type I error for multiple comparisons are generally applied
(e.g., Bonferroni correction; Hinkle et al. 1996). By contrast,
methods for the application of corrections for Type I error to
individuals are not as well known and therefore used rarely.
It may be possible to provide a statistically reliable basis
for inferences about drug treatment-related cognitive change
in individuals. First, we suggest that performance data for
the individual should not be considered representative of the
population from which the individual was selected, but
rather as representative of the population of data for that
individual. Hence, statistical inferences about the presence
of cognitive change pertain only to the individual and not the
population. Importantly, the assumptions that operate for
inferential statistics in groups must also be satisfied for
individuals. Thus, distributions of the data for individuals
should be normal and possess homogeneity of variance
between treatment conditions. Every effort should be made
to meet these assumptions by utilizing strategies such as
increasing the number of observations, improving the metric
properties of tests and minimizing the effects of extraneous
factors such as practice and motivation (Anastasi and Urbina
1997; Bland and Altman 1995). In a series of recent studies,
we identified a series of outcome measures from the
CogState battery http://www.cogstate.com) that satisfy these
statistical requirements (Mollica et al. 2005; Mollica et al.
2004; Collie et al. 2003a,b).
Statistical questions about whether the cognitive change
observed in an individual is statistically reliable also
require that any observed change be compared to some
estimate of the normal variability in performance over time.
Recent considerations of this issue have shown how
variability estimated in groups of individuals measured
over time can be used to provide a denominator against
which change in performance in individuals can be
compared (Bland and Altman 1996; Collie et al. 2002;
Jacobson and Truax 1991). Importantly though, the most
powerful of these techniques are parametric and once again
require that data have the appropriate characteristics
(Anastasi and Urbina 1997; Bland and Altman 1996).
Second, the definition of a criterion for change on any
individual cognitive measure should be a statistical
difference rather than an absolute difference in perfor-
mance. Statistical criteria appreciate that any specific value
nominated as a criterion will contain error and conse-
quently place confidence intervals around this criterion
value. Third, where multiple criteria for change are applied
to the same individual, the potential for a Type I error can
be controlled by considering simultaneously the number of
outcome measures, the criterion for abnormality on any one
measure, and the number of abnormal tests results
necessary for a classification of change and whether the
hypothesis is one- or two-tailed. For example, a series of
simulations based on the binomial probability distributions
show that to contain Type I error at less than 5% (with a
two-tailed hypothesis) in a test battery that yields nine
outcome measures, change should be classified as reliable
only when there is a decline in performance of 1.96 SD or
greater on at least three of the outcome measures. If the
criterion for change on any one single measure is defined as
a decrease of one standard deviation, then a classification
of reliable change would require this to occur for all nine
measures to preserve the false positive classification rate at
5% (see Ingraham and Aiken 1996 for further discussion of
this point). However, the Ingraham and Aiken (1996)
simulations assume that the outcome measures used are
independent. Therefore, these simulations may be too
conservative for classification criteria applied to questions
of cognitive change. It would be useful to compute the
actual false positive classification rate associated with any
criteria for cognitive change. Another method for mini-
mizing the risk of Type I error when multiple performance
measures are used is to summarize all outcome measures
into a single composite change score (see Rasmussen et al.
2001, Mollica et al. 2004). In fact, composite change scores
may be more appropriate for identifying treatment-related
cognitive impairment in individuals as it is possible that a
psychoactive drugs will give rise to a generalized but subtle
change over a range of cognitive functions rather than to
large impairments or improvements in measures of specific
cognitive functions (as would be required to see a
deterioration of greater than 1.96 SD).
Benzodiazepines are a class of drug for which the effects
on cognitive function in groups of healthy individuals are
well understood (de Visser et al. 2003; Vester and Volkerts
2004; Stewart 2005). The benzodiazepine alprazolam is
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known to induce marked impairment in cognitive function
after a single dose as low as 0.5 mg and this impairment has
been observed most reliably in psychomotor, attentional,
and memory functions (Vester et al. 2002; Vester and
Volkerts 2004; Snyder et al. 2005). Alprazolam reaches
maximum concentration in plasma (e.g., Cmax) in approxi-
mately 1 h and has few side effects (D’Souza et al. 2001;
Wong et al. 1998). Given these features, alprazolam
treatment provides a good challenge for measuring the
magnitude of impairment in individual subjects according
to the statistical and methodological principles outlined
above. Because all of the studies of alprazolam related
cognitive impairment have been conducted in groups, the
extent to which alprazolam-related cognitive impairment
can be identified reliably in the cognitive performance of
individuals has not been established. Recently, we reported
that the CogState test battery and the Groton Maze
Learning Test (GMLT) developed by us specifically to
assess cognitive change were sensitive to the effects of 1
and 0.5 mg of alprazolam on cognitive function (Snyder et
al. 2005). We found that, when analyzed at a group level,
an acute dose of 1 mg gave rise to significant impairment
across all aspects of cognitive function measured.
Although the magnitude of impairment was greater for
tests of attention and psychomotor speed (e.g., effect sizes
for the difference between baseline and posttreatment
approximately 1) compared to the deterioration detected
on measures of memory and executive (e.g., effect sizes
for the difference between baseline and posttreatment
approximately 0.5).
The cognitive measures used in the Snyder et al. (2005)
study had been developed specifically so that they yielded
data with optimal metric properties for the detection of
change (Mollica et al. 2004; Mollica et al. 2005) and these
measures had been challenged in a group of subjects who
were given a moderate dose of alprazolam in a highly
controlled clinical trial environment. Therefore, the data
from the Snyder et al. (2005) study provided a strong basis
for challenging empirically the statistical and methodolog-
ical principles argued to be important for the classification
of treatment-related cognitive change in individuals. The
aim of the current study was to reanalyze some of the data
from our earlier study in accord with these recommenda-
tions to determine the extent to which cognitive change
could be classified in individual subjects. To achieve this,
the stability of performance of each outcome measure was
estimated from the multiple pretreatment assessments.
These estimates were then used as the reference against
which the magnitude of any treatment-related cognitive
change could be determined. We then compared the
incidence of treatment-related cognitive change in the
group who had been challenged with a single acute 1-mg
dose of alprazolam and those who received placebo. We
hypothesized that the statistical and methodological ap-
proach developed in this study would allow classification
of cognitive change in a large proportion of subjects who
had received an acute dose of alprazolam, while at the same
time maintaining a low rate of false positive classification
in individuals who had received placebo.
Materials and methods
Subjects
The data from 26 healthy individuals was analyzed in the
current study (14 had received alprazolam and 12 had
received placebo). All were in good health as determined
by medical history, physical examination, vital signs,
electrocardiogram, and clinical laboratory measurements,
The exclusion criteria for the selection of the study subjects
were if any of the following conditions applied: routine use
of sedative or other psychoactive medication, participation
in any investigational or marketed drugs during the 30-day
period before the start of the study (baseline), pregnancy or
lactation, a history of significant adverse reaction to
gabapentin, pregabalin, or benzodiazepine anxiolytics,
significant urine concentration of any illicit drug, a history
of glaucoma or red–green color blindness, or a history of
any central nervous system condition such as Parkinson’s
disease, significant head trauma (head injury with loss of
consciousness within the past 5 years), brain tumors, major
depression, alcohol or illicit drug abuse. All subjects
provided written informed consent before any study
procedures. This study was conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice and
the protocol was approved by institutional ethics commit-
tees. As this study as conducted at the level of individual
subjects, only those who provided baseline and postdrug
cognitive data for all performance measures were included.
Using this additional criterion, two patients who had been
randomized to the placebo condition in the initial group
study (e.g Snyder et al. 2005) were not analyzed in the
current study. There was no difference between the groups
of subjects randomized to placebo or alprazolam for weight
(alprazolam mean=78.4 kg, SD=17.1, placebo=82.3,
SD=18.1, t<1), height (alprazolam=172.1 cm SD=8.1;
placebo mean=171.3 cm, SD=9.2, t<1), age (alprazolam
mean=31.2 years SD=8.2; placebo mean=32.4; SD=9.6;
t<1), education level (alprazolam mean=12 years SD=2.3;
placebo mean=12 years; SD=3.1; t<1), or gender (alpraz-
olam number of males=14/14; placebo number of
males=11/12 χ2=0.1).
Study design
Subjects were assigned randomly to receive placebo TID or
1 mg alprazolam TID in a double blind parallel groups
design. The present analyses utilized performance data at
baseline and after the first dose of study medication. The
study blind was maintained by administering the same
number of identical capsules to each subject within each
cohort. The administration and ingestion of study medica-
tion was supervised by clinical research personnel. Cog-
nitive testing required approximately 30 min in total
(20 min for the CogState battery and 10 min for the
GMLT). These cognitive tests were administered three
times for more than three days before baseline (day 3,
day 2, day 1), then at baseline and then again at Cmax for
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alprazolam. Because the time to maximum concentration
(Tmax) for alprazolam is approximately 1 h post dosing
(Wong et al. 1998; D’Souza et al. 2001) and the test battery
required 30 min to complete testing always began 45 min
after dosing so that we bracketed around Tmax for this drug.
The order of administration for the CogState and GMLT
was pseudo-randomized across subjects and test sessions to
control for test order effects, although the tests in the
CogState battery were always given in the same order. Data
from the Day 3 assessment was classified as a familiariza-
tion assessment and was not considered in the current
analysis.
Apparatus
The cognitive test battery consisted of eight different tests of
psychomotor function, attention, executive function, mem-
ory, and problem solving/strategy use. All were presented on
lap top computers. The tests were selected because of their
brevity, demonstrated utility for within-subjects experimen-
tal designs, and for the parametric properties of their
outcome measures (cf., Falleti et al. 2003; Schroder et al.
2004). The CogState battery consisted of seven tasks and
has been described elsewhere in detail (Falleti et al. 2003;
Mollica et al. 2004; Snyder et al. 2005). The tests used the
outcome measure they generate and the cognitive functions
that theymeasure are summarized in Table 1. These tasks are
in the form of card games that were presented in succession
on a green background. At the beginning of each task,
written instructions were presented to the left of the screen to
indicate the rule. Each subject was then given an interactive
demonstration and, once they had successfully given a
sufficient number of correct responses to demonstrate their
awareness of the rules, the task began. A grey keyboard
resembling a computer keyboard appeared in the lower half
of the computer screen and the cards associated with each
task were presented in the upper half. The subject was
required to respond with two keys throughout the entire
battery, either the “D” or “K” key. For right hand dominant
subjects “Yes” responses were indicated by pressing the “K”
key and “No” responses by pressing the “D”. This mapping
was reversed for left-hand dominant subjects. The beginning
of each new task was indicated with a shuffling of the cards.
An error beep sounded if a subject pressed an incorrect key
at any time. Each trial was time-limited and the same error
beep sounded if a response was not made within the required
time. A subject could pause the test at any stage using the
escape key. The performance measures for each task were
the speed of the response (i.e., reaction time recorded in
milliseconds) and the accuracy of response (i.e., correct or
incorrect). The seven tasks included in the battery were as
follows.
1. Detect A single card was presented at in the middle of
the monitor and the subject was required to respond as
soon as the card turned face up. The instructions
provided by the “on-screen” helper were: “Has the card
turned face up? If yes, press the ‘K’ key”. This was
completed three times throughout the battery: at the
beginning, in the middle (before the working memory
task), and at the end. On each occasion, this task
continued until 25 correct responses were recorded or
the maximum allowed time elapsed (2 min). For the
current study, performance was averaged across the
three trials.
2. Monitor Five cards were presented face-up in the
middle of the screen. Horizontal white lines were
marked above and below these cards. The five cards
move randomly in either an upwards or downwards
direction. The direction of each card was independent
of the others. The instructions provided by the “on-
screen” helper were: “Press ‘yes’ as soon as a moving
card touches a white line”. Following this, the card
returned to the middle of the screen and began to move
again. A response was classified as being correct if the
subject pressed the “K” key after one of the cards had
touched the upper or lower white line. If the “K” key
was not pressed when a card touched either line, an
error buzzer sounded until a response was made. This
task continued until 25 correct responses were
recorded or until the maximum allowed time elapsed
(2 min).
3. Identify Awhite card with either a black or red square
in its center was presented in the middle of the
computer screen. The instructions provided by the “on-
screen” helper were: “Is the face-up card red? If the
answer is yes press the ‘K’ key, if the answer is no
press the ‘D’ key”. Once the subject demonstrated that
they understood the rules, the cards reverted to
conventional playing cards and the participants
responded to the color of the cards’ suit. This task
continued until 25 correct responses were recorded or
the maximum allowed time elapsed (2 min).
4. Match Two white cards, aligned horizontally, with
either a black or red square on each were presented in
the middle of the screen. The instructions provided by
the “on-screen” helper were: “Are the two face-up
cards the same color? If the answer is yes then press the
‘K’ key, if the answer is no, press the ‘D’ key”. Once
the subject demonstrated that they understood the
rules, the cards reverted to conventional playing cards.
This task continued until 25 correct responses were
recorded or the maximum allowed time elapsed
(2 min).
5. Remember one back Two playing cards were presented
in the middle of the screen; one was face-up and the
other face-down. The instructions provided by the “on-
screen” helper were: “Does the face-up card exactly
match the one before? If the answer is yes, press the
‘K’ key, if the answer is no, press the ‘D’ key”. The
correct answer for the first card was always “no” as no
card had previously been shown. After the subject had
pressed the “D” key, the card turned over and a new
card appeared face-up. If this card was the same as the
previous card, the subject was required to press “K”
(yes), if not “D” (no) should have been pressed. This
task continued until 25 correct responses were
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recorded or the maximum allowed time elapsed
(2 min).
6. Sort Six pairs of cards (each pair aligned vertically)
were presented in a display at the top of the computer
screen. A single pair of cards (also aligned vertically)
was presented at the bottom of the screen, which may
or may not have matched one of the pairs above. The
instructions provided by the “on-screen” helper were:
“Do the two face-up cards match one of the pairs
above? If yes, press the ‘K’ key, if no, press the ’D’
key”. Once the subject responded, a new pair of cards
was presented at the bottom of the screen. This task
continued until 25 correct responses were recorded or
the maximum allowed time elapsed.
7. Learn Five card pairs (aligned vertically) were presented
at the top of the screen. A single card pair (aligned
vertically) was also presented at the bottom of the screen.
The instructions provided by the “on-screen” helper
were “Do the two face-up cards match one of the pairs
above? If yes, then press the ‘K’ key, if no, press the ‘D’
key”. As soon as the subject pressed the “K” or “D” key,
a new pair of cards was shown at the bottom of the
screen. If the single pair of cardsmatched one of the pairs
of cards in the display, the pair at the top of the screen
turned face down. This continued until all of the card
pairs at the top of the screen were turned face down, with
the exception of the central pair, which remained face up
as a control task. The subject was required to remember
the card pairs at the top of the screen and to determine
whether the pair at the bottom of the screen matched one
of these. The pairs of cards presented at the bottom of the
screen could be correct pairs or foils (i.e., card pairs that
were incorrect). Each incorrect pair was presented only
once during the test, whereas each correct pair was
presented five times. The probability that the pair of
cards presented was correct was 25%. When the subject
responded correctly, the card pair shown moved to the
top of the screen (indicating that it was one of the hidden
pairs). After an incorrect response, the card pair
remained in the same location but was shuffled to the
bottom of the deck while the error buzzer sounded. This
task continued until 25 correct responses were recorded
or the maximum allowed time elapsed
– The Groton Maze Learning Task (GMLT) was
presented on a tablet computer (i.e., a portable
computer with a touchscreen) where the subject
used an electronic stylus to respond. Once again
feedback was given by the computer.
8. Maze Learning The Groton Maze Learning Test
(GMLT) was developed by one of the authors (P.J.
S.), and it is based on an earlier hidden maze task
developed by Milner (1965). The GMLT has been
used to examine spatial memory and spatial working
memory (see Darby and Walsh 2005, for review), and
it consists of a 10×10 grid of tiles presented on a
computer touchscreen in which 28-step pathway was
hidden. The tile at the start and the finish were
indicated in locations at the top left and bottom right
locations of the grid. The subject was instructed to
move one tile from the start location and then to
continue one tile at a time toward the end. While
moving through the hidden maze, subjects were
required to adhere to two rules; first, they could not
move diagonally and second, they could not move
back to a location where they had previously been.
After each move made by the subject, the computer
indicated whether this was correct (i.e., was the next
step in the pathway) or incorrect (was not the next step
in the pathway, or that the subject had broken one of
the rules). If the choice was incorrect, the subject was
required to touch the last correct tile and then choose a
different tile to advance toward. When the subject
completed the pathway, he or she repeated this process
for a total of five successive learning trials. On each
trial, the number and type of errors (first errors vs
perseverative errors) made as well as the time (in ms)
to complete each trial was recorded. This current paper
reports results for only a measure of problem solving
and spatial working memory on this task (the number
of correct moves per second, averaged over the five
learning trials). Twenty well-matched alternate forms
for this test were selected in pseudo-random order, to
Table 1 Cognitive functions assessed in the current study and their performance measures
Cognitive task Cognitive function measured Measure type Metric
Detect Psychomotor Speed Log10RT
Monitor Vigilance Speed Log10RT
Identify Simple attention Speed Log10RT
Match Simple attention Speed Log10RT
Remember one back Executive function (working memory) Speed Log10RT
Remember one back Executive function (working memory) Accuracy Arcsine percentage accuracy
Sort Executive function and complex attention (sorting) Accuracy Arcsine percentage accuracy
Maze learn Executive function (problem solving/spatial working memory) Efficiency Moves/second
Learn Associate learning and memory Accuracy Arcsine percentage accuracy
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ensure that no subject completed the same hidden path
form more than once throughout the study.
Data analysis
Data cleaning and preprocessing
Data from all practice trials was removed from data bases.
All data from the CogState tasks were then inspected and
anticipatory responses (RTs <100 ms) and abnormally slow
responses (RTs >3,500 ms) were considered errors and
excluded from further analysis. The number of trials on
which correct responses occurred was also computed and
this was expressed as a proportion of the total trials. As
distributions of percent correct from the participant group
were characterized by positive skew, the percent correct
value for each individual for each measure was normalized
using an arcsine transformation (Anastasi and Urbina
1997). The speed of decisions was computed by taking the
average reaction time of correct responses for each task.
Inspection of the distributions of reaction times for correct
responses in each individual indicated a negative skew on
all of the outcome measures. Therefore, before computing
the average reaction time, the response time for each trial
was normalized using a logarithmic base 10 transformation
(Anastasi and Urbina 1997). For each assessment of the
GMLT, the time required to complete the pathway on each
of the five trials was measured and a total time to complete
the five trials computed. Because there are 28 correct steps
required to complete each trial of the pathway, the total
time was divided by 140 (i.e., 5×28) to yield a measure of
correct moves/second. Because this measure was distrib-
uted normally, it was not transformed.
Stability of cognitive performance over time
Although the stability of the performance measures used in
this study has been established performance across the
three baseline assessments (Day 2, Day 1, and baseline)
was analyzed in the 26 subjects to determine whether any
learning effects were present and to compute stability
estimates for each test. Baseline data from each subject for
each task was submitted to a series of one-way analyses of
variance (ANOVA). The within-subject standard deviation
(WSD) was derived from the ANOVA output by comput-
ing the square root of the mean square residual term (Bland
and Altman 1996). The coefficient of variation was then
calculated for each measure by expressing the WSD as a
function of the performance on each test averaged over the
three baseline assessments (i.e., grand mean).
Effect of treatment on cognitive performance
of individuals
Computation of reliable change for individual perfor-
mance measures To quantify the magnitude of cognitive
change associated with each performance measure under
Table 2 Group mean (SD) performance across the three baseline assessments, stability (within subject standard deviation, WSD) and
coefficient of variation (CoVar)
Performance measure B1 (n=26) B2 (n=26) B3 (n=26) F Mean B WSD CoVar
Detect 2.51 2.49 2.51 1.3 2.5 0.04 0.02
(speed) (0.1) (0.08) (0.08) (0.07)
Monitor 2.53 2.53 2.53 0 2.53 0.08 0.03
(speed) (0.11) (0.11) (0.13) (0.09)
Identify 2.69 2.71 2.74 1.8 2.71 0.09 0.03
(speed) (0.15) (0.08) (0.08) (0.08)
Match 2.84 2.85 2.84 0.1 2.84 0.04 0.01
(speed) (0.07) (0.1) (0.08) (0.07)
Remember one back 2.87 2.85 2.84 1.3 2.85 0.07 0.02
(speed) (0.13) (0.11) (0.08) (0.09)
Remember one back 1.16 1.26 1.33 1.2 1.25 0.13 0.10
(acc) (0.29) (0.3) (0.26) (0.22)
Maze learn 1.14 1.12 1.15 0.8 1.14 0.10 0.09
(efficiency ) (0.21) (0.3) (0.22) (0.18)
Sort 1.11 1.08 1.15 0.8 1.11 0.11 0.10
(acc) (0.34) (0.24) (0.26) (0.23)
Learn 0.83 0.85 0.9 1.6 0.86 0.11 0.13
(acc) (0.22) (0.19) (0.18) (0.18)
The F value given here is the effect of time derived from an analysis of variance comparing performance between the three baseline
assessments
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the placebo and alprazolam conditions in each individual
subject, a cognitive change score was computed for each
outcome measure using the following formula:
cognitive change score measure að Þ
¼ baseline measure að Þ  post baseline measure að Þ
WSD measure að Þ of the group
In this equation, “measure a” is any one of the nine
performance measures (detailed in Table 1), the WSD is the
within-subject standard deviation derived from the three
baseline conditions for the same measure, baseline is the
mean of the three baseline scores for “measure a”, and
postbaseline (both shown on Table 2) is the score on
“measure a” at Cmax.
Classification of treatment related cognitive change
in individual subjects
Cognitive change scores were used to classify individuals
as showing treatment (placebo or alprazolam) related
cognitive impairment in two ways. First, previous simula-
tions indicated that for nine outcome measures, a change in
performance of 1.96 or greater on two or more tests would
retain the Type I error for classification of impairment at
less than 5% under a two-tailed hypothesis (Ingraham and
Aiken 1996; although these simulations assume tests are
independent). Because the cognitive change scores had
been standardized using the WSD, cut-scores for abnor-
mality could be derived directly from the known properties
of normal distributions. Therefore, individuals who
showed cognitive change scores of ≤−1.96 or ≥1.96 on
two or more outcome measures were classified as showing
treatment-related cognitive change (p<0.05, two tailed).
The second method defined treatment -related cognitive
change by identifying whether subtle impairment in cogni-
tive function occurred across all measures (Rasmussen et al.
2001). A composite cognitive change score was computed
by summing the cognitive change scores across the nine
performance measures for each individual. Because the
composite cognitive change score required that cognitive
change scores be summed, the characteristics of the data
distribution changed. Therefore, it was necessary to
restandardize these scores to use the properties of a normal
distribution to guide decisions about abnormality. A group
mean and standard deviation of composite cognitive change
scores was then computed for the placebo group and the
alprazolam group. The composite cognitive change scores
for all subjects was then standardized using the mean and
SD of the composite cognitive change score in the placebo
group. A subject in the alprazolam group with a composite
cognitive change score of greater than the placebo group
mean ≤−1.96 or ≥1.96 standard deviations (p<0.05, two
tailed) was classified as showing treatment-related cognitive
impairment. Classifications of treatment-related cognitive
change in the placebo group were deemed to be false
positive classifications; the false positive rate observed for
the placebo group was used to check the accuracy of the
theoretically derived false positive rates (e.g., Ingraham and
Aiken 1996). The number of individuals who met the
criterion for treatment-related cognitive change in each
group was compared using Fisher’s exact test.
Results
Stability of cognitive performance over time
Group means and their relative WSD for the three baselines
in the 26 subjects are shown in Table 2. The ANOVAs
indicated that no practice effects occurred on any of the
measures (F values given in Table 2). The estimates of
stability (WSD) and the coefficient of variation for each
measure are also shown in Table 2. Multiplication of the
coefficient of variation by 100 allows the stability of each
performance measure to be expressed as a percentage. The
speed measures performance varied less than 5% over
assessments. The stability of accuracy measures was a little
lower with variance generally around 10%.
Classification of treatment-related cognitive change
in individual subjects
Table 3 shows the number cognitive change scores ≤1.96
for each performance measure in the alprazolam and
placebo conditions. For no measure did performance
improve after either placebo or alprazolam. Compared to
the placebo condition, the number of individuals in the
alprazolam group showing reliable change on a cognitive
measure was significantly greater only for the CogState
Match and Learn performance scores. Table 4 shows the
number of individuals classified as showing treatment-
related cognitive change cognitively impaired (two or more
cognitive change scores ≤−1.96 or a standardized compos-
ite cognitive change score of ≤−1.96). When treatment-
Table 3 Number of subjects classified as showing cognitive change







Detect (speed) 1 6 0.06
Monitor (speed) 3 1 0.3
Identify (speed) 0 4 0.1




Remember one back (acc) 1 4 0.3
Maze learn (efficiency) 0 4 0.1
Sort (acc) 1 4 0.3
Learn (acc) 2 8 0.03
P derived from Fisher’s exact probability (two tailed)
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related cognitive change was defined as cognitive change
scores of ≤−1.96 on two or more measures, 71% of
individuals in the alprazolam condition (hits) and no
subjects in the placebo condition (false positive) met the
criteria for impairment. When treatment-related cognitive
change was defined as a composite cognitive change score
of ≤1.96, the hit rate increased to 93% although this was
accompanied by an increase in the false positive rate to 8%
(i.e., one subject in the placebo condition was classified as
having impairment). When either criterion was sufficient,
these rates remained the same with 93% of subjects in the
alprazolam condition and 8% of subjects in the placebo
group classified as showing treatment related cognitive
change. Finally, the between group comparison of the
composite cognitive change scores was significant [t(28)=
5.1; p<0.01] yielding an effect size (Cohen’s d) of 2.0 for
the magnitude of the difference.
Discussion
The aim of this study was to determine whether a novel
but theoretically derived statistical and methodological
approach to the classification of cognitive change in
individuals could identify cognitive change in individuals
who had received an acute 1 mg dose of alprazolam.
The dose and compound were selected because their
sedative actions are well known and because previous
studies had shown that relatively low doses reliably
induce cognitive deterioration in healthy adults. Thus,
we expected that performance on the cognitive tasks
would become worse after treatment. By deriving change
scores for each cognitive performance measure and a
composite score of all measures, statistically reliable
cognitive impairment was identified for 93% of individ-
uals who had received alprazolam. The same method and
analysis identified only 8% of individuals who had
received only placebo. Therefore, statistical rules that
required change on a subset of change scores derived
from the nine performance measures or from a com-
posite score computed from the sum of change scores
from all nine measures showed excellent sensitivity to
cognitive change while maintaining false classification
rates at acceptable levels. Thus, the current method and
analysis showed an excellent sensitivity and specificity
for alprazolam related cognitive deterioration in individ-
uals. These findings, although preliminary, suggest that
statistically reliable decisions about the effects of ben-
zodiazepine drugs on cognition can be made for
individuals.
The reliable identification of cognitive impairment in
individuals required both the statistical methods described
in this study and the methodological soundness of the study
design. First, the cognitive tasks used in the study were
chosen because they have been designed for rapid
administration without giving rise to practice effects
(Collie et al. 2003a,b; Falleti et al. 2003, Mollica et al.
2005). Therefore, the test battery could be given repeatedly
at relatively short retest intervals (days) to allow estimation
of performance stability before randomization. The multi-
ple baselines also allowed a stable estimate of baseline
performance to be estimated, against which the effect of
alprazolam could be compared. The performance measures
derived from the tasks used in this study were chosen to
measure cognitive change because they have been shown
to be distributed normally (after transformation), not
limited by floor or ceiling effects, not subject to range
restriction, and contain no skew (Mollica et al. 2004).
These good metric properties and the repeatability of tasks
meant that each performance measure chosen showed good
stability over time according to the method of Bland and
Altman (1996). In fact, each estimate of variation in
performance over time within individuals (i.e., WSD) was
systematically smaller than the corresponding estimates of
variability in performance between individuals at any one
time (i.e., the group standard deviation on any one
assessment, see Table 2). In the past, some studies seeking
to identify individuals for whom significant posttreatment
cognitive change has occurred have used the pretreatment
group standard deviation as an estimate of population
stability for their statistical decision rules (e.g., CABG
studies, see Collie et al. 2003a,b; for a review). This
method may be the only available for estimating of normal
variability over time when there is a single pretreatment
assessment. However, had we have used the group baseline
standard deviation to estimate the background variability in
cognitive test performance, then the sensitivity of the
statistical analysis and method would have been reduced
considerably. This observation emphasizes the importance
of multiple baseline or pretreatment assessments.
A group analysis of this same data indicated that
performance on all of the measures used in this study was
significantly worse than baseline after the single acute dose
of 1 mg of alprazolam, whereas there were no significant
changes in performance over the same assessments for
group who received placebo (Snyder et al. 2005). For the
alprazolam group, the magnitude of deterioration in
performance was largest for the measures of attention (effect
sizes of approximately 0.8). Deterioration in memory and
executive functions was not as severe (effect sizes of
approximately 0.5). Interestingly, unlike this analysis, and
indeed other group studies of the effects of alprazolam
(Snyder et al. 2005; Verster et al. 2002; Vermeeren et al.
1995), the analysis of individual performance identified no
performance measures that were uniquely sensitive to the
effects of alprazolam on cognitive function. For example,
Table 4 Number (%) of individuals who meet the criteria for










0 1 (8.3) 1 (8.3)
Alprazolam
(n=14)
10 (71.4) 13 (92.9) 13 (92.9)
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compared to the placebo condition, individuals treated with
alprazolam showed greater rates of abnormality on each of
the cognitive measures used. However, this difference was
significant only for measures of speed on the detection and
matching tasks and for accuracy on the learning task. Even
for the measures with a significantly greater sensitivity to
alprazolam-related cognitive change than placebo, the rate
of abnormality was never greater than 53% (eight subjects).
Despite this nonspecificity, 71% of individuals met the
criterion for cognitive change that required that abnormal
change to occur on two or more of the performance
measures. This indicates that alprazolam-related cognitive
impairment occurred on different performance measures in
different individuals. This nonspecificity for individuals is
also reflected in the finding that the composite change score
criterion was more sensitive to the effects of alprazolam than
the two abnormal score criterion. Thus, it appears that
alprazolam did cause performance on each of the tasks to
deteriorate, although the magnitude of this deterioration
varied across performance measures in different individuals.
In the majority of cases, the magnitude of deterioration was
not statistically significant (i.e.,<−1.96). However, when
summed across performance measures, these subtle but
systematic changes combined to yield statistically signifi-
cant deterioration in the composite cognitive change scores
for all but two individuals who had received alprazolam and
only one individual who had received placebo. One likely
reason for the qualitatively different patterns of abnormality
across the performance measures between the group and
individual analyses is that the superior statistical power of
hypotheses tested for groups allows a more detailed analysis
of the effect of the drug on different tests. At the individual
level, there are fewer observations of performance and
therefore greater potential for error to obscure results. In this
case, the composite score acts to maximize the statistical
power by concentrating all of the observations conducted on
the same individual into a single measure. Interestingly,
when the composite score for each individual was treated as
an outcome measure and compared in a group analysis, the
magnitude of the difference detected (d=2) was much larger
than the difference between groups for any of the individual
measures (see Snyder et al. 2005). This suggests that the use
of the composite score may also bring greater statistical
power in the analyses of cognitive change in groups.
Despite the sensitivity of the cognitive tasks and the
analytic method, two individuals in the alprazolam group
did not show the expected deterioration in cognitive
function (Fig. 1). This could reflect either error in the
performance measures or the cognitive tasks from which
they were derived, error in statistical criteria used,
noncompliance with the pre- or posttreatment testing
requirements, or that these individuals’ cognitive function
truly did not change in response to the drug. We believe the
latter explanation to be correct. In both of these individuals,
the composite score was positive (Fig. 1), suggesting that
cognitive performance improved with alprazolam. Inspec-
tion of their raw data indicated no unusually slow or
variable responses or unusually slow performance that
would suggest lack of understanding, low motivation, or
noncompliance. Furthermore, neither of these subjects
showed significant cognitive deterioration on any one of
the nine performance measures. Therefore, it appears that
these two subjects are true nonresponders, at least after
1 mg alprazolam. Clinical studies in patients with panic
disorder suggest that nonresponse rates to alprazolam can
be as high as 20% (Verster and Volkerts 2004). Of course,
this is decided on clinical variables rather than cognitive
outcomes as used in this study. However, the method
developed in this study could be applied to any data,
including that from standardized clinical rating scales.
Such an application may provide a more rigorous basis to
assist clinical decisions of nonresponse or response.
Because most psychopharmacological studies of alprazo-
lam have compared groups of subjects, there are no
estimates of the rate of nonresponders. It is possible that
increases in dose would lead the cognitive nonresponders
identified in this study to show some cognitive deteriora-
tion. It is important to note that the aim of the current study
was to validate the method for detecting and classifying
cognitive change in individuals. Therefore, further study is
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composite cognitive change score
deterioration improvement
P<0.05Fig. 1 Distribution of raw
composite cognitive change
scores in the placebo (black
bars) and alprazolam (grey
bars) conditions. Dotted line
indicating p<0.05 (two tailed) is
set at the mean composite cog-
nitive change score in the pla-
cebo group mean minus 1.96 SD
units, also derived from the
placebo group
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required to determine whether the nonresponders identified
in this study would show cognitive deterioration at higher
doses of alprazolam or whether a cognitive endpoint might
also be useful in determining treatment response to
alprazolam in individuals with anxiety disorder.
The methodology applied in this study also classified
one individual who received placebo as showing cognitive
decline. This positive classification (8%) was similar with
the error rate of the classification rules used (e.g., p<0.05).
Had the score required for abnormality been lowered
further to avoid this false positive classification (e.g., to
p<0.01), then the sensitivity of the method to alprazolam-
related cognitive decline would have also decreased (e.g.,
at p<0.01 the hit rate for the composite score was 11/14 or
78.5%). Therefore, it appears that the criteria chosen for
abnormality provided an appropriate balance between
sensitivity and specificity to alprazolam-related cognitive
decline in healthy adults.
In a previous study we applied these same cognitive tests
and statistical methods to measure treatment response in a
group of children with attention deficit disorder who had
been treated with 7.5 mg of D-amphetamine (Mollica et al.
2004). It is worth considering this study for two reasons.
First, the aim of the study of Attention Deficit Hyperac-
tivity Disorder was to detect improvement in cognitive
function in the children after treatment (as opposed to the
cognitive deterioration expected in this study). The results
of these two studies suggest strongly that the CogState test
battery, and the statistical method developed in this study
can be used to identify both positive and negative treatment
response. Second, in the study of treatment response to D-
amphetamine, we applied the statistical method developed
in this study to selected clinical rating scales and found a
high degree of agreement between classifications of
cognitive response and symptomatic response. These data
illustrate that the method described has good clinical
validity and can be applied to other types of outcome
measure. There were a number of limitations operating in
the current study. First, this was a reanalysis of previous
data in which the results were known. Hence, it is
necessary to now apply the method detailed in this study
in a de novo study of another compound known to alter
cognitive function. Second, the current study used a
parallel group design rather than a complete crossover.
Although this would be unlikely to have affected the results
obtained in this study, a crossover design would require the
subjects to complete twice as many reassessments (i.e., in
both treatment conditions) and to provide two baselines.
This should improve further the estimates of stability of the
pretreatment performance. Third, the current method
should be applied to a study with a larger pool of subjects,
ideally those who also vary on characteristics that are
known to influence treatment response (e.g., weight,
gender, genotype, etc.). The method for classifying cogni-
tive change developed in this study should be sensitive and
specific in these newer studies, but outcome measures such
as the composite score should covary in a predictable
manner with these factors in the treatment group. Never-
theless, despite these limitations, the results of the current
study provide a firm basis for refinement through further
challenge.
In conclusion, a novel methodological and statistical
development to classify treatment-related cognitive decline
in individuals did adequately identify those who showed
true cognitive change, while keeping false positive classi-
fication rates at acceptably low levels. When the cognitive
performance of individuals alone was examined, measures
that contain good metric properties provide reliable
estimates of performance. With measures that contain
metric properties appropriate for measuring change, certain
statistical methods can be applied to determine whether
cognitive impairment has occurred at the individual level.
As the results demonstrate, more individuals were
classified as impaired following 1 mg alprazolam com-
pared to placebo, and this was most evident in the
composite cognitive change scores that were derived
across all the performance measures, rather than the single
scores derived for each measure. This suggests that for
future studies, the calculation of a composite cognitive
change score across appropriate measures is one method
that could be applied.
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